Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Publication ,  Journal Article
Fuh, KC; Secord, AA; Bevis, KS; Huh, W; ElNaggar, A; Blansit, K; Previs, R; Tillmanns, T; Kapp, DS; Chan, JK
Published in: Gynecol Oncol
December 2015

BACKGROUND: To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). METHODS: A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. RESULTS: Of 277 patients (median age: 58years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C+Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7months, and median overall survival (OS) was 14.3 and 10.5months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n=19, OS of 20.4months), taxanes (n=55, OS of 20.2months), gemcitabine (n=106, OS of 14.1months), topotecan (n=43, OS of 13months), and cyclophosphamide (n=21, OS of 13months). There was no significant difference in toxicities between the C+Bev vs. Bev alone group. CONCLUSION: This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

December 2015

Volume

139

Issue

3

Start / End Page

413 / 418

Location

United States

Related Subject Headings

  • Young Adult
  • Topotecan
  • Taxoids
  • Survival Rate
  • Retrospective Studies
  • Response Evaluation Criteria in Solid Tumors
  • Radiography
  • Polyethylene Glycols
  • Peritoneal Neoplasms
  • Ovarian Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fuh, K. C., Secord, A. A., Bevis, K. S., Huh, W., ElNaggar, A., Blansit, K., … Chan, J. K. (2015). Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecol Oncol, 139(3), 413–418. https://doi.org/10.1016/j.ygyno.2015.06.041
Fuh, Katherine C., Angeles A. Secord, Kerri S. Bevis, Warner Huh, Adam ElNaggar, Kevin Blansit, Rebecca Previs, Todd Tillmanns, Daniel S. Kapp, and John K. Chan. “Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.Gynecol Oncol 139, no. 3 (December 2015): 413–18. https://doi.org/10.1016/j.ygyno.2015.06.041.
Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, et al. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecol Oncol. 2015 Dec;139(3):413–8.
Fuh, Katherine C., et al. “Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.Gynecol Oncol, vol. 139, no. 3, Dec. 2015, pp. 413–18. Pubmed, doi:10.1016/j.ygyno.2015.06.041.
Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, Previs R, Tillmanns T, Kapp DS, Chan JK. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecol Oncol. 2015 Dec;139(3):413–418.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

December 2015

Volume

139

Issue

3

Start / End Page

413 / 418

Location

United States

Related Subject Headings

  • Young Adult
  • Topotecan
  • Taxoids
  • Survival Rate
  • Retrospective Studies
  • Response Evaluation Criteria in Solid Tumors
  • Radiography
  • Polyethylene Glycols
  • Peritoneal Neoplasms
  • Ovarian Neoplasms